- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Harvard Business School Launches Precision Trials Challenge
Harvard Business School has launched a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.
The Health Care Initiative at Harvard Business School (HBS) has launched the Precision Trials Challenge (www.precisiontrialschallenge.org), a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.
The challenge is open to all and will accept applications at (www.precisiontrialschallenge.org until March 13, 2016. A panel of judges will select one winner and two runners-up to share a $100,000 prize. The winner will be announced in April and have the opportunity to present at the prestigious 2016 Personalized Medicine Conference.
“Advancements in science and technology in the past ten years have led to great advances in precision medicine,” said HBS professor Richard Hamermesh. “However, many of the big challenges facing precision medicine today are actually business challenges. How can we develop business models that support the advancement of precision medicine? How can we get new therapies to market faster and at a lower cost? Our Precision Trials Challenge will help answer these questions by encouraging conversation and helping to put leading-edge ideas into practice.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
